<DOC>
	<DOC>NCT01577459</DOC>
	<brief_summary>This is a randomized, double-blinded, placebo-controlled, crossover study to evaluate the pressor effects of pseudoephedrine when administered with TR-701 FA in healthy adult volunteers.</brief_summary>
	<brief_title>A Phase 1 Crossover Study of Blood Pressure and Heart Rate Response</brief_title>
	<detailed_description>Eligible subjects will be randomized to 1 of 2 possible treatment sequences (N=9 per sequence) on Study Day 1. Subjects will receive oral 200 mg TR 701 FA or Placebo for TR 701 FA once daily for 5 days during each treatment period, with a 2 day washout between periods (72 hours between doses). On Study Day 5 of each treatment period, subjects will also receive oral 60 mg PSE.</detailed_description>
	<mesh_term>Torezolid phosphate</mesh_term>
	<criteria>Male or female subjects between 18 and 45 years of age, inclusive Healthy males and females with no clinically significant abnormalities identified by a detailed medical history Body mass index ≥ 19.0 kg/m2 and ≤ 31.0 kg/m2 Systolic blood pressure &gt; 130 mmHg or &lt; 90 mmHg measured after 10 minutes supine at the Screening Visit and Study Day 1 Diastolic blood pressure &gt; 90 mmHg or &lt; 60 mmHg measured after 10 minutes supine at the Screening Visit and Study Day 1 Heart rate &gt; 90 bpm or &lt; 50 bpm measured after 10 minutes supine at the Screening Visit and Study Day Known allergy or hypersensitivity to PSE</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>